PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.338
https://www.valueinhealthjournal.com/article/S1098-3015(19)32716-0/fulltext
Title :
PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32716-0&doi=10.1016/j.jval.2019.09.338
First page :
Section Title :
Open access? :
No
Section Order :
10274